^
    5d
    DEL-MRD-CHID: Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, Rong Tao
    New P2 trial • Minimal residual disease • Circulating tumor DNA
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    5d
    Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=200, Recruiting, Chinese PLA General Hospital | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • fludarabine IV • aclarubicin
    6d
    Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs-STAT3 Pathway. (PubMed, Adv Sci (Weinh))
    By targeted delivery to M2 macrophages, chidamide sufficiently inhibited HDACs, enhanced STAT3 acetylation, reprogrammed M2 proportion into M1 phenotype, and ultimately suppressed lymphoma growth in vivo. With reduced dosage and adverse reactions, our Chid@M2pep-EVs system provides a new translational strategy for treating refractory/relapsed lymphoma.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Epidaza (chidamide)
    11d
    Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring. (PubMed, Cancer Discov)
    We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti-PD-1/CTLA-4) in metastatic PDAC patients and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemo-immunotherapy efficacy.
    Journal
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    gemcitabine • albumin-bound paclitaxel • Epidaza (chidamide)
    13d
    Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    |
    azacitidine • decitabine • Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    13d
    Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (clinicaltrials.gov)
    P2, N=50, Recruiting, Ou Bai, MD/PHD
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    13d
    Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (clinicaltrials.gov)
    P3, N=200, Recruiting, Ou Bai, MD/PHD
    New P3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Epidaza (chidamide)
    14d
    The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions. (PubMed, Ann Hematol)
    B-ALL with MEF2D fusions frequently demonstrates multilineage involvement, poor response to conventional chemotherapy, and extramedullary infiltration. Incorporating venetoclax and the histone deacetylase inhibitor chidamide into induction, salvage, or preconditioning regimens may probably improve outcomes for MEF2D-positive patients, though certainly required further clinical validation.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MEF2D (Myocyte Enhancer Factor 2D)
    |
    KRAS mutation • NRAS mutation
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    14d
    CDB0369: Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Completed, Ou Bai, MD/PHD | N=20 --> 30 | Recruiting --> Completed
    Trial completion • Enrollment change
    |
    Epidaza (chidamide)
    14d
    Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. (clinicaltrials.gov)
    P2, N=30, Recruiting, Daihong Liu
    New P2 trial
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule)
    |
    TP53 mutation • CD22 positive
    |
    Epidaza (chidamide)
    17d
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    18d
    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Chinese PLA General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Sep 2025
    Enrollment closed • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin